KdT Ventures

We’re excited to announce the close of our oversubscribed $100M Fund IV to invest in early-stage frontier science companies! ???? Congrats to the team and Phil Grayeski Ph.D., who got promoted to Managing Partner and Patrick Malone, MD PhD , to Partner. ???? Excited for the future and sharing our release here: https://lnkd.in/eXhrdxTn

We are all about building the physical layer here at KdT. Forget NFTs. Index engineered the non-fungible #physical token - Authentica - at a time when verification seems essential for country of origin (think tariffs) and growing food safety concerns.

?? Montara Therapeutics Secures $28M in Oversubscribed Seed Expansion!?? We’re thrilled to announce the close of a $20M oversubscribed Seed expansion, bringing total funding to $28M. Participation increased from all existing investors: SV Health Investors' Dementia Discovery Fund (DDF), Two Bear Capital, Dolby Family Ventures, and KdT Ventures.?BEVC?and other investors also joined the round. This funding is a testament to the incredible progress our team has made towards our mission to advance?#BrainOnly? therapies?for CNS diseases, and will enable us to: ? File an IND for our lead rare epilepsy program within 12 months ? Advance our neurodegeneration program toward development candidate nomination ? Progress a third, undisclosed program We’re grateful to our investors and partners for their continued belief in our mission and the Montara team for executing at a high level, bringing us one step closer to delivering transformative therapies for patients. ?? ???Full press release linked here: https://lnkd.in/e3JqDXHn #biotech??? #drugdevelopment????#BrainOnly ?? #MontaraTherapeutics ?

Cain McClary, MD’s wife needed him out of the house. Back in 2017, McClary was working from home as the lead pathologist for a health tech company. But his mind was tracking technological advancements in the life sciences industry — the falling cost of sequencing, or AlexNet’s computer neural network besting human pathologists in diagnosing melanoma. “I just wanted to run after that as fast as possible,” he recalled. But it was his wife who gave him the push: “Honestly, it was her saying, like, ‘You need to compete. Like, this isn’t high enough octane for you, and I can’t have you around the house like this.’” Eight years later, McClary’s firm, KdT Ventures, has invested in around 75 startups. The firm raised its fourth fund last October, collecting $100 million to invest in seed rounds for therapeutics, computational biology, and life science tools companies. Read the article and the other VCs featured in this STAT article by Allison DeAngelis: https://lnkd.in/etB7iNVz

The world might feel a bit shitty right now, but Zymo is here to help. This past quarter, Zymochem achieved the industrial biotech equivalent of ‘Human POC’ (for my therapeutically-minded colleagues)—scaling up their production process to 45,000 liters to create the world’s first biodegradable, bio-based super absorbent polymer (SAP). And SAP just happens to be the absorbent workhorse behind a parent’s #1 friend and a landfills #1 enemy: the baby diaper. #industrialbiotech #diapers #zymo #scaleup

We at KdT Ventures are thrilled to announce a our partnership with NGM Bio for NGM313, a Phase 2-ready FGFR1c/β-Klotho receptor complex agonistic antibody initially discovered and developed by NGM Bio. As part of this partnership, we're launching a new company dedicated to advancing NGM313's development in a #raredisease indication—marking the first non-metabolic application to be explored for this promising therapeutic. Our new venture is preparing to initiate a Phase 2 proof-of-concept study in 2025. We’re thrilled to have the opportunity to drive NGM313's development forward and look forward to collaborating closely with NGM Bio to unlock its full potential and treat patients in need. Read the Full Article Here:?https://lnkd.in/gt4m4zv4

KdT Ventures portfolio company Dyno Therapeutics announces their expanded partnership with Roche- designing and delivering AAV capsids to translate the promise of generic medicine for patients in need. Congratulations on this milestone!

Great opportunity for scientist-entrepreneurs interested in building a neuro-focused startup!

FirstWord Pharma covers our recent news: The adoption of AI tools in drug development has surged this year, but Cain McClary, MD has been betting on the technology since "day one" of KdT Ventures, which he founded in 2017. The firm closed its fourth fund at $100 million on Wednesday — bringing its total assets to $250 million — with plans to back early-stage startups that exist at the intersection of data science and life science. "The ability to leverage AI to accelerate compound identification, optimise clinical trials, and predict drug interactions has transformative potential in biotech," McClary told FirstWord. Read the article by Elizabeth Eaton: https://lnkd.in/efENAKWc

Venture Capital Journal reporter Iris Dorbian covers today’s news: https://lnkd.in/ewWa6_Yq